Logo image of GBIO

GENERATION BIO CO (GBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GBIO - US37148K2096 - Common Stock

5.68 USD
+0.09 (+1.61%)
Last: 12/31/2025, 8:02:55 PM
Fundamental Rating

2

Taking everything into account, GBIO scores 2 out of 10 in our fundamental rating. GBIO was compared to 530 industry peers in the Biotechnology industry. The financial health of GBIO is average, but there are quite some concerns on its profitability. GBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GBIO had negative earnings in the past year.
In the past year GBIO has reported a negative cash flow from operations.
GBIO had negative earnings in each of the past 5 years.
GBIO had a negative operating cash flow in each of the past 5 years.
GBIO Yearly Net Income VS EBIT VS OCF VS FCFGBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of GBIO (-51.38%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -123.87%, GBIO is doing worse than 60.19% of the companies in the same industry.
Industry RankSector Rank
ROA -51.38%
ROE -123.87%
ROIC N/A
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
GBIO Yearly ROA, ROE, ROICGBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

GBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBIO Yearly Profit, Operating, Gross MarginsGBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

GBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GBIO has been increased compared to 1 year ago.
GBIO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GBIO Yearly Shares OutstandingGBIO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
GBIO Yearly Total Debt VS Total AssetsGBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -9.83, we must say that GBIO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.83, GBIO is not doing good in the industry: 71.70% of the companies in the same industry are doing better.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.83
ROIC/WACCN/A
WACC8.82%
GBIO Yearly LT Debt VS Equity VS FCFGBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

GBIO has a Current Ratio of 4.44. This indicates that GBIO is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.44, GBIO perfoms like the industry average, outperforming 51.89% of the companies in the same industry.
GBIO has a Quick Ratio of 4.44. This indicates that GBIO is financially healthy and has no problem in meeting its short term obligations.
GBIO has a Quick ratio (4.44) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 4.44
GBIO Yearly Current Assets VS Current LiabilitesGBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

GBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.35%, which is quite impressive.
Looking at the last year, GBIO shows a very negative growth in Revenue. The Revenue has decreased by -17.82% in the last year.
EPS 1Y (TTM)57.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.35%
Revenue 1Y (TTM)-17.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.9%

3.2 Future

The Earnings Per Share is expected to grow by 7.09% on average over the next years.
GBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -26.69% yearly.
EPS Next Y33.1%
EPS Next 2Y30.28%
EPS Next 3Y17.61%
EPS Next 5Y7.09%
Revenue Next Year-39.28%
Revenue Next 2Y-48.11%
Revenue Next 3Y-16.02%
Revenue Next 5Y-26.69%

3.3 Evolution

GBIO Yearly Revenue VS EstimatesGBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
GBIO Yearly EPS VS EstimatesGBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GBIO. In the last year negative earnings were reported.
Also next year GBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBIO Price Earnings VS Forward Price EarningsGBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GBIO Per share dataGBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as GBIO's earnings are expected to grow with 17.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.28%
EPS Next 3Y17.61%

More info and screens

0

5. Dividend

5.1 Amount

GBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

GENERATION BIO CO

NASDAQ:GBIO (12/31/2025, 8:02:55 PM)

5.68

+0.09 (+1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-11 2026-03-11/amc
Inst Owners65.44%
Inst Owner Change-86.58%
Ins Owners2.79%
Ins Owner Change0.05%
Market Cap38.28M
Revenue(TTM)15.27M
Net Income(TTM)-62.63M
Analysts78.18
Price Target9.01 (58.63%)
Short Float %0.82%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)33.67%
Min EPS beat(2)-7.33%
Max EPS beat(2)74.68%
EPS beat(4)2
Avg EPS beat(4)22.43%
Min EPS beat(4)-7.33%
Max EPS beat(4)74.68%
EPS beat(8)3
Avg EPS beat(8)-10.52%
EPS beat(12)6
Avg EPS beat(12)-5.45%
EPS beat(16)8
Avg EPS beat(16)-3.34%
Revenue beat(2)1
Avg Revenue beat(2)30.49%
Min Revenue beat(2)-75.81%
Max Revenue beat(2)136.78%
Revenue beat(4)3
Avg Revenue beat(4)106.66%
Min Revenue beat(4)-75.81%
Max Revenue beat(4)301.43%
Revenue beat(8)7
Avg Revenue beat(8)145.01%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-70.88%
PT rev (3m)-66.98%
EPS NQ rev (1m)-38.83%
EPS NQ rev (3m)-124.55%
EPS NY rev (1m)-6.86%
EPS NY rev (3m)-6.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-47.48%
Revenue NY rev (1m)3.91%
Revenue NY rev (3m)3.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.51
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-9.34
EYN/A
EPS(NY)-5.99
Fwd EYN/A
FCF(TTM)-17.02
FCFYN/A
OCF(TTM)-16.86
OCFYN/A
SpS2.27
BVpS7.5
TBVpS7.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.38%
ROE -123.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.33%
Cap/Sales 7.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 4.44
Altman-Z -9.83
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)120.26%
Cap/Depr(5y)130.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.35%
EPS Next Y33.1%
EPS Next 2Y30.28%
EPS Next 3Y17.61%
EPS Next 5Y7.09%
Revenue 1Y (TTM)-17.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-78.9%
Revenue Next Year-39.28%
Revenue Next 2Y-48.11%
Revenue Next 3Y-16.02%
Revenue Next 5Y-26.69%
EBIT growth 1Y7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.86%
OCF growth 3YN/A
OCF growth 5YN/A

GENERATION BIO CO / GBIO FAQ

Can you provide the ChartMill fundamental rating for GENERATION BIO CO?

ChartMill assigns a fundamental rating of 2 / 10 to GBIO.


Can you provide the valuation status for GENERATION BIO CO?

ChartMill assigns a valuation rating of 0 / 10 to GENERATION BIO CO (GBIO). This can be considered as Overvalued.


Can you provide the profitability details for GENERATION BIO CO?

GENERATION BIO CO (GBIO) has a profitability rating of 0 / 10.


What is the earnings growth outlook for GENERATION BIO CO?

The Earnings per Share (EPS) of GENERATION BIO CO (GBIO) is expected to grow by 33.1% in the next year.